1st Quarter - Report

SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE for SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE

Firm
Client
Income
—
Expenses
$140,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.3070/S.1599, Department of Labor, Health and Human Services, Education and Related Agencies Appropriations Act, 2012, primarily matters related to appropriations for cancer research and cancer screening programs. H.R.2219, Department of Defense Appropriations Act, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-74, Consolidated Appropriations Act, 2012, primarily matters related to appropriations for cancer research, cancer screening programs and Congressional directed medical research programs. Pub. Law No. 112-25, the Budget Control Act of 2011, primarily matters related to funding of cancer research and CDC cancer prevention and control programs. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing an order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Support of draft congressional resolution for reauthorization of the Prescription Drug User Fee Act (PDUFA), primarily matters related to drug shortages, drug approval and patient access.

LobbyistCovered position, as disclosed
ALLISON COHEN —
KAREN HANDEL —

Contacted: Centers For Disease Control & Prevention (CDC); Natl Institutes of Health (NIH); SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Bills named: H.R. 2746 (112th), H.R. 3699 (112th), H.R. 3839 (112th), S. 2113 (112th), S. 2236 (112th), H.R. 3705 (112th), H.R. 2499 (112th), H.R. 2245 (112th), H.R. 1483 (112th), S. 296 (112th), H.R. 3067 (112th), H.R. 2219 (112th), H.R. 3102 (112th), S. 1599 (112th), H.R. 3070 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.